Compare GSK plc (GSK) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tesla, Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 16.1× GSK plc's market cap, and GSK plc pays a 3.9% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Tesla, Inc. for 88 Days on average.
| GSK | TSLA | |
|---|---|---|
Market Cap | $91.88B | $1.48T |
Volume | 7,730,529 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $489.88 |
52-Week Low | $43.24 | $298.16 |
Typical Hold Time | 93 Days | 88 Days |
Enterprise Value | $111.88B | $1.45T |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Tesla trades at $375.03, down 0.68% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss ($0.33 actual vs. $0.50 expected) but beat expectations in the previous two quarters. Revenue declined to $94.83B in 2025 with net income margin compressing to 4%. Recent news highlights regulatory approval for driver assistance software in Europe and a potential cheaper EV launch.
Tesla faces near-term headwinds from slowing auto growth and elevated valuations (P/E 347), but long-term optimism centers on autonomous driving and energy segments. Analyst consensus price target of $441.36 suggests 18% upside, though execution risks and competition remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
